Analysis of endogenous peptides bound by soluble MHC class I molecules: A novel approach for identifying tumor-specific antigens

European Journal of Immunology

Volumn 32, Issue 1, 2002, Pages 213-222

  Barnea, Eilon ^a   Beer, Ilan ^b   Patoka, Renana ^a   Ziv, Tamar ^a   Kessler, Ofra ^a   Tzehoval, Esther ^c   Eisenbach, Lea ^c   Zavazava, Nicholas ^d   Admon, Arie ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b IBM HAIFA RESEARCH LAB   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Cancer vaccine; Mass spectrometry; MHC class 1; Peptide antigen

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN; PEPTIDE; TUMOR ANTIGEN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANTIGEN PURIFICATION; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY TUMOR; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROSTATE TUMOR; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; FEMALE; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEPTIDES; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, PROTEIN; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0036146275     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200201)32:1<213::AID-IMMU213>3.0.CO;2-8     Document Type: Article

References (52)

1. Mechanisms of MHC class I-restricted antigen processing
2. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry
3. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
4. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes
5. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
6. Contribution of mass spectrometry to contemporary immunology
7. New opportunities for the development of cancer immunotherapies
8. Tumor antigens recognized by T cells
9. T cell defined tumor antigens
10. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy
11. SYFPEITHI: Database for MHC ligands and peptide motifs
12. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
13. Description and prediction of peptide-MHC binding: The 'human MHC project'
14. Association of class I major histocompatibility heavy and light chains induced by viral peptides
15. Phenotypic analysis of antigen-specific T lymphocytes
16. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
17. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
18. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo
19. Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique
20. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
21. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization
22. Genetic engineering of an H-2Dd/Q10b chimeric histocompatibility antigen: Purification of soluble protein from transformant cell supernatants
23. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations
24. Purified truncated recombinant HLA-B7 molecules abrogate cell function in alloreactive cytotoxic T lymphocytes by apoptosis induction
25. Large-scale production of class I bound peptides: Assigning a signature to HLA-B*1501
26. A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity
27. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: Estimation of the affinity of a T cell receptor for MHC
28. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: Sequence motif, quantitative binding, and molecular modeling of the complex
29. The murine liver-specific nonclassical MHC class I molecule Q10 binds a classical peptide repertoire
30. Complexity among constituents of the HLA-B*1501 peptide motif
31. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma
32. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes
33. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
34. Quantitative and biochemical characterization of soluble HLA class I antigens shed by cultured human cells
35. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach
36. A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex associated peptides that eliminates the need for bioassays
37. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism
38. HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation
39. Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER
40. The polymorphic epithelial mucin: Potential as an immunogen for a cancer vaccine
41. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen
42. Novel breast-tumor-associated MUC1-derived peptides: Characterization in Db-/- x beta2 microglobulin null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain
43. An overview of the MAGE gene family with the identification of all human members of the family
44. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
45. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas
46. Synthesis and antitumor activity of an inhibitor of fatty acid synthase
47. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma
48. The DNA methylation machinery as a target for anticancer therapy
49. Targeting DNA methyltransferase in cancer
50. Method to compare collision-induced dissociation spectra of peptides: Potential for library searching and subtractive analysis
51. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method
52. Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling